uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Regulation of vitamin D3 25-hydroxylases in dermal fibroblasts and prostate cancer LNCaP cells
Uppsala University, Medicinska vetenskapsområdet, Faculty of Pharmacy, Department of Pharmaceutical Biosciences, Pharmaceutical Biochemistry.
Article in journal (Refereed) Submitted
URN: urn:nbn:se:uu:diva-97882OAI: oai:DiVA.org:uu-97882DiVA: diva2:172977
Available from: 2008-11-28 Created: 2008-11-28Bibliographically approved
In thesis
1. Regulation of Vitamin D 25-hydroxylases: Effects of Vitamin D Metabolites and Pharmaceutical Compounds on the Bioactivation of Vitamin D
Open this publication in new window or tab >>Regulation of Vitamin D 25-hydroxylases: Effects of Vitamin D Metabolites and Pharmaceutical Compounds on the Bioactivation of Vitamin D
2008 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

A 700bp portion of the promoter of CYP2D25, the porcine microsomal vitamin D 25-hydroxylase was isolated and sequenced. The computer analysis of the sequence revealed the existence of a putative VDRE at 220 bp upstream of the transcription start site. A CYP2D25 promoter-luciferase reporter plasmid was constructed in order to study the transcriptional regulation of the gene. Treatment with the vitamin D metabolites calcidiol and calcitriol suppressed the promoter, provided that the nuclear receptors VDR and RXR were overexpressed. Phenobarbital was also capable of suppressing the promoter if the nuclear receptors PXR or CAR were overexpressed.

The 25-hydroxylases are not expressed solely in liver but in a wide array of other organs as well. It is therefore possible at least in theory to study the vitamin D 25-hydroxylation in human subjects using cells from extrahepatic organs, from which biopsy retrieval is easier than from the liver. Dermal fibroblasts are frequently used to study different pathological conditions in human subjects and they are easy to come by. Dermal fibroblasts were shown to express two vitamin D 25-hydroxylases: CYP27A1 and CYP2R1. The expression pattern of CYP2R1 displayed considerable interindividual variation. The fibroblasts were also capable of measurable vitamin D 25-hydroxylation, which makes dermal fibroblasts a possible tool in studying vitamin D 25-hydroxylation in human subjects.

Little is known about the regulation of expression and activity of the human vitamin D 25-hydroxylases. Therefore dermal fibroblasts – expressing CYP2R1 and CYP27A1 – and human prostate cancer LNCaP cells, that express CYP2R1 and CYP2J2, were treated with calcitriol and phenobarbital and efavirenz, two drugs that give rise to vitamin D deficiency. Treatment decreased the mRNA levels of CYP2R1 and CYP2J2 provided that the treated cells also expressed the necessary nuclear receptors. CYP27A1 did not respond to any of the treatments. The treatments also managed to decrease the 25-hydroxylating activity of the cells.

The results show that vitamin D 25-hydroxylases can be regulated by both endogenous and xenobiotic compounds.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2008. 47 p.
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy, ISSN 1651-6192 ; 87
CYP2D25, vitamin D 25-hydroxylase, transcriptional regulation, vitamin D, CYP2R1, CYP2J2, CYP27A1, phenobarbital, efavirenz, fibroblast, LNCaP
National Category
Pharmaceutical Sciences
urn:nbn:se:uu:diva-9412 (URN)978-91-554-7362-4 (ISBN)
Public defence
2008-12-19, C8:321, BMC, Husargatan 3, Uppsala, 09:15
Available from: 2008-11-28 Created: 2008-11-28Bibliographically approved

Open Access in DiVA

No full text

By organisation
Pharmaceutical Biochemistry

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Total: 145 hits
ReferencesLink to record
Permanent link

Direct link